4//SEC Filing
Nader Francois 4
Accession 0000899243-22-026684
CIK 0001827506other
Filed
Jul 24, 8:00 PM ET
Accepted
Jul 25, 7:35 PM ET
Size
17.0 KB
Accession
0000899243-22-026684
Insider Transaction Report
Form 4
Nader Francois
Director
Transactions
- Purchase
Common Stock
2022-07-19$3.52/sh+50,000$176,000→ 50,000 total - Purchase
Common Stock
2022-07-20$3.62/sh+52,000$188,240→ 102,000 total - Other
Common Stock
2022-07-25+138,500→ 386,932 total(indirect: By LLC) - Other
Common Stock
2022-07-21−248,432→ 87,735 total(indirect: By Trust) - Other
Common Stock
2022-07-21+248,432→ 248,432 total(indirect: By LLC) - Purchase
Common Stock
2022-07-21$3.72/sh+36,500$135,780→ 138,500 total - Other
Common Stock
2022-07-25−138,500→ 0 total
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.38 to $3.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.51 to $3.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]Represents the transfer of shares held by the Francois Nader 2020 Trust to FN TALS LLC for no consideration.
- [F4]These shares are held in a trust for the benefit of the Reporting Person's spouse and child. The Reporting Person's spouse and child are trustees of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F5]These shares are held by a limited liability company of which the Reporting Person serves as the sole member, with sole voting and investment control over the securities held thereby. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F6]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.595 to $3.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F7]Represents the transfer of shares held by the Reporting Person to FN TALS LLC for no consideration.
Documents
Issuer
Talaris Therapeutics, Inc.
CIK 0001827506
Entity typeother
Related Parties
1- filerCIK 0001365343
Filing Metadata
- Form type
- 4
- Filed
- Jul 24, 8:00 PM ET
- Accepted
- Jul 25, 7:35 PM ET
- Size
- 17.0 KB